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Closure of Paravalvular Regurgitation After
Percutaneous Valve-in-Ring Implantation
Ignacio Cruz-Gonzalez, MD, PHD, Javier Rodríguez-Collado, MD, Antonio Arribas-Jimenez, MD, PHD,
Manuel Barreiro-Perez, MD, Juan Carlos Rama-Merchan, MD, PHD, Pedro L. Sanchez, MD, PHDA 73-year-old man with permanent atrial ﬁbril-lation, coronary artery disease revascularizedwith coronary artery bypass grafting, mitral
valve repair with a 30-mm Carpentier Physio ring
(Edwards Lifesciences, Irvine, California), tricuspid
valve repair with a 34-mm Edwards MC3 ring
(Edwards Lifesciences), and implantation of a 23-mm
CarboMedics aortic valve (Sorin Group, Milan, Italy)
in 2008 was admitted because of recurrent congestive
heart failure secondary to severe mitral regurgita-
tion that was due to mitral ring dysfunction. Associ-
ated comorbidities included thrombocytopenia and
chronic renal failure. The patient was not considered
a surgical or MitraClip (Abbott Laboratories, Chicago,
Illinois) candidate by the heart team. Transcatheter
mitral valve-in-ring (ViR) was considered the most
suitable treatment.
Using a transseptal approach over a venoarterial
loop, a 29-mm Edwards SAPIEN XT valve (Edwards
Lifesciences) was correctly implanted within the
mitral ring (Figure 1A); however, echocardiography
demonstrated signiﬁcant paravalvular regurgitation
between the ring and the valve (Figure 1B). Balloon
post-dilation was not considered an option because
of the risk of para-ring dehiscence or distortion of
the ring.
Percutaneous closure of the leak was scheduled.
A 5  7-mm leak was measured by 3-dimensional
transesophageal echocardiogram. After transseptalFrom the Cardiology Department, University Hospital of Salamanca, IBSAL,
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wire using an AL2 catheter, a venoarterial loop was
created, and a Torq-Veu 6-F catheter (St. Jude Medi-
cal, St. Paul, Minnesota) was advanced over the loop
through the leak. An Amplatzer Vascular Plug III
10  5-mm device (St. Jude Medical) was deployed
(Figures 1C and 1D), and the regurgitation was signif-
icantly reduced.
Post-operative recurrence of mitral valve regur-
gitation after mitral valve repair may occur (1). In
this subgroup of patients, percutaneous treatment
could be an option to avoid surgery. MitraClip
implantation has been described (2), and the
feasibility of ViR implantation has been reported
(3). A major concern of ViR is that the valve must
accommodate an asymmetric oval-shaped ring and
make it circular; a distortion of the valve itself
may lead to regurgitation and/or to paravalvular
regurgitation because of suboptimal apposition to
the ring. We describe the ﬁrst-in-man percutaneous
transseptal closure of paravalvular regurgitation as
a result of suboptimal apposition of the valve to
the ring.
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FIGURE 1 Closure of Paravalvular Regurgitation After Percutaneous ViR Implantation
(A) Transseptal valve-in-ring implantation (ViR). (B) Echocardiographic image showing paravalvular regurgitation between the ring and the
valve. (C) Paravalvular leak closure with an Amplatzer Vascular Plug III device (St. Jude Medical, St. Paul, Minnesota). (D) Three-dimensional
echocardiographic image showing the correct position of the device.
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